Oncolytic viruses (OVs) represent a cutting-edge approach in cancer immunotherapy, characterized by their ability to selectively infect and destroy tumor cells by inducing immunogenic cell death and triggering an anti-tumor immune response, without affecting healthy cells. Of the different OVs, HSV-1 shows promising clinical applications due to its potent oncolytic ability, broad infectivity range, ease of genetic manipulation, induction of long-term cellular immune response, and the availability of drugs to control its proliferation.

A new collaborative study from Pusan National University and Yonsei University suggests that the FOLFIRINOX regimen showed numerically improved survival outcomes compared to current standards such as FOLFOX, FOLFIRI, and nal-IRI/FL, while maintaining manageable toxicity levels. These findings suggest that FOLFIRINOX could serve as a promising second-line treatment option for patients with advanced BTC following first-line chemotherapy failure, warranting further validation through prospective clinical studies.

Colorectal cancer (CRC) remains a leading cause of cancer-related deaths worldwide, largely due to metastasis and therapeutic resistance. However, the molecular mechanisms driving these processes are still not fully understood.Colorectal cancer (CRC) remains a leading cause of cancer-related deaths worldwide, largely due to metastasis and therapeutic resistance. However, the molecular mechanisms driving these processes are still not fully understood.